PMID- 24653547
OWN - NLM
STAT- MEDLINE
DCOM- 20141112
LR  - 20231110
IS  - 2505-0044 (Electronic)
IS  - 2505-0044 (Linking)
VI  - 11
IP  - 1
DP  - 2014
TI  - Modified Yupingfeng formula for the treatment of stable chronic obstructive 
      pulmonary disease: a systematic review of randomized controlled trials.
PG  - 1-14
AB  - BACKGROUND: Chronic obstructive pulmonary disease (COPD), is a very common 
      disease of respiratory system. An increasing number of clinical trials on 
      Yupingfeng formula in the management of stable COPD have been performed. However, 
      the evidence base for it remains unknown. This review aims at assessing the 
      efficacy, and safety of modified Yupingfeng formula in the treatment of stable 
      COPD through a systematic review of all available randomized controlled trials. 
      MATERIALS AND METHODS: Literature retrieval was conducted using four English 
      databases (CENTRAL, PubMed, EMBASE, and ISI Web of Science), and four Chinese 
      databases (CBM, CNKI, VIP, and WANFANG), from respective inception to January 
      2013, and supplemented with a manual search. Review authors independently 
      extracted the trial data, and assessed the quality of each trial. Methodological 
      quality was assessed by Cochrane risk of bias and Jadad's scale. The following 
      outcomes were evaluated: (1) lung function; (2) 6-minute walk distance (6MWD); 
      (3) effective rate; (4) serum levels of IgA, IgG and IgE; and (5) adverse events. 
      Data were analyzed using STATA 12.0 software. RESULTS: A total of nine studies 
      involving 660, stable COPD patients were identified. Patients from all studies 
      included in this review were randomized to receive Yupingfeng formula combined 
      with Western medications in comparison with Western medications. In general, the 
      methodological quality of the included trials was poor. The results of this 
      systematic review indicates that, compared with Western medications alone, the 
      use of Yupingfeng formula, if combined with Western medications could 
      significantly improve FEV1 (WMD = 0.30L; 95%CI: 0.19, 0.42), FEV1/FVC ratio (SMD 
      = 0.69; 95%CI: 0.48, 0.91), 6MWD (WMD = 31.73m; 95% CI: 19.29, 44.17), and 
      effective rate (RR = 1.24; 95% CI: 1.10, 1.41), and increase the serum levels of 
      IgA (WMD = 0.25; 95%CI: 0.16, 0.34) and IgG (WMD = 1.10; 95%CI: 0.53, 1.68), but 
      no difference was found in the serum IgE levels (WMD = 0.47; 95%CI: -0.32, 1.27) 
      between the two groups. No serious adverse events were reported. CONCLUSIONS: 
      Within the limitations of this systematic review, we may conclude that compared 
      with Western medications alone, Yupingfeng formula, when combined with Western 
      medications can provide more benefits for patients with stable COPD, without any 
      serious adverse reactions being identified. However, these benefits need to be 
      further confirmed through high-quality prospective placebo-controlled trials that 
      should be strictly conducted in accordance with methodological principles and 
      procedures.
FAU - Zhong, Yunqing
AU  - Zhong Y
AD  - Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi 
      University of Traditional Chinese Medicine, Nanning, People's Republic of China.
FAU - Wang, Xiufeng
AU  - Wang X
AD  - Department of Herpetology, The First Affiliated Hospital of Guangxi University of 
      Traditional Chinese Medicine, Nanning, People's Republic of China.
FAU - Xu, Guanglan
AU  - Xu G
AD  - Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi 
      University of Traditional Chinese Medicine, Nanning, People's Republic of China.
FAU - Mao, Bing
AU  - Mao B
AD  - Pneumology Group, Department of Integrated Traditional Chinese and Western 
      Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of 
      China.
FAU - Zhou, Wei
AU  - Zhou W
AD  - Pneumology Group, Department of Integrated Traditional Chinese and Western 
      Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of 
      China.
FAU - Min, Jie
AU  - Min J
AD  - Pneumology Group, Department of Integrated Traditional Chinese and Western 
      Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of 
      China.
FAU - Jiang, Hongli
AU  - Jiang H
AD  - Pneumology Group, Department of Integrated Traditional Chinese and Western 
      Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of 
      China.
FAU - Diao, Xiang
AU  - Diao X
AD  - Chinese Evidence-Based Medicine/Cochrane Center, West China Hospital, Sichuan 
      University, Chengdu, People's Republic of China.
FAU - Fu, Juanjuan
AU  - Fu J
AD  - Department of Respiratory and Sleep Medicine, John Hunter Hospital, Hunter 
      Medical Research Institute, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20131102
PL  - Nigeria
TA  - Afr J Tradit Complement Altern Med
JT  - African journal of traditional, complementary, and alternative medicines : AJTCAM
JID - 101232990
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (yupingfeng)
SB  - IM
MH  - *Apiaceae
MH  - *Astragalus Plant
MH  - *Atractylodes
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - *Phytotherapy
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy
PMC - PMC3957235
OTO - NOTNLM
OT  - Systematic review
OT  - Yupingfeng formula
OT  - chronic obstructive pulmonary disease
EDAT- 2014/03/22 06:00
MHDA- 2014/11/13 06:00
PMCR- 2014/11/02
CRDT- 2014/03/22 06:00
PHST- 2014/03/22 06:00 [entrez]
PHST- 2014/03/22 06:00 [pubmed]
PHST- 2014/11/13 06:00 [medline]
PHST- 2014/11/02 00:00 [pmc-release]
AID - jAJT.v11.i1.pg1 [pii]
PST - epublish
SO  - Afr J Tradit Complement Altern Med. 2013 Nov 2;11(1):1-14. eCollection 2014.